Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Medacta Group SA
  6. News
  7. Summary
    MOVE   CH0468525222

MEDACTA GROUP SA

(MOVE)
  Report
Delayed Swiss Exchange  -  11:30 2022-09-29 am EDT
81.40 CHF   -1.09%
09/21Medacta's MyKnee R Platform Becomes Part Of Revision Surgeries In US
MT
09/21Medacta announces first revision surgeries in the US using the unique-on-the-market and innovative MyKnee R patient-specific solution
EQ
09/09Transcript : Medacta Group SA, H1 2022 Earnings Call, Sep 09, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Medacta : Announces Launch of NextAR Shoulder Augmented Reality Surgical Platform in Europe and the US

04/13/2022 | 06:45am EDT

Developed with the help of worldwide orthopaedic expert surgeons to improve efficiency and precision in total shoulder replacement, while supporting the advancement of personalized surgery, NextAR Shoulder has been successfully used to treat more than 200 patients in Europe and the United Statesfrom its first introduction in June 2021.

"I recall the first time the concept of NextAR technology was introduced to me. I was really surprised and enthusiastic and I immediately thought - I want to be part of this project!", said Prof. Dr. med. Matthias Zumstein at the Engeriedspital in Bern Switzerland. "Multiple wetlabs have assisted us in fine-tuning the surgical approach and have increased my confidence in working in close relationship with the technology. Now, after several surgeries performed, I can say that NextAR Shoulder represents a real added value to my surgical practice. Even though I believed in this project when we started working on it, I never thought we would achieve such an extremely beneficial result for the surgeon."

Prior to surgery, the surgeon uses a 3D virtual model of the patient's shoulder in order to choose the best implant and position for restoring the patient's unique anatomy. NextAR Shoulder enhances the preoperative strategy planning with unique intraoperative orientation assessments, allowing surgeons to accurately track the position of instruments and implants in real-time through the proprietary single-use NextAR TS Tracking System.
"Technology in shoulder replacement surgery is always advancing, but never so rapidly as I have seen in recent years. I can now plan the surgery more precisely than ever before using three-dimensional CT scanning and software to make the best decisions regarding optimal implant configuration for each individual patient and their unique anatomy." said John-Erik Bell, M.D. at the Dartmouth-Hitchcock Medical Center (DHMC) in Lebanon, New Hampshire. "The advantage of NextAR technology is in allowing me to precisely and accurately replicate my preoperative plan in real time, during surgery, without having to look away from my patient for navigation assistance. Once I have planned my optimal shoulder replacement strategy for my patient, I feel confident that NextAR will enable me to execute my plan even more accurately. Now that I have become comfortable using this technology, I can say that NextAR navigation is a real advantage for me during surgery, especially during complex cases."
NextAR Shoulder leverages synergy with the complete and convertible Medacta Shoulder System to provide surgeons with the possibility of tailoring the implant choice to the patient's needs. Moreover, this innovative technology is part of Medacta's MySolutions Personalized Ecosystem, an advanced network of digital solutions designed to improve patient outcomes and healthcare efficiency.
Medacta showcases its latest surgical innovations at numerous orthopaedics congresses:
12thVal d'Isère Advanced Shoulder Course, April 14-16, Val d'Isère, France
Antwerp Shoulder Arthroplasty Course, April 21-22, Antwerp, Belgium
Shoulder360° - The Comprehensive Shoulder Course, April 28-30, Miami, US
Paris International Shoulder Course, July 7-9, Paris, France
SECEC-ESSE, September 7-9, Dublin, Ireland
NextAR Shoulder is also supported by Medacta's M.O.R.E. Institute, which offers surgeons ongoing tailored help through a strong education network as they seek to incorporate new technologies.
Visit our brand-new portal nextar-shoulder.medacta.com to discover more about this unique technology.

Disclaimer

Medacta Group SA published this content on 13 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 April 2022 10:44:08 UTC.


© Publicnow 2022
All news about MEDACTA GROUP SA
09/21Medacta's MyKnee R Platform Becomes Part Of Revision Surgeries In US
MT
09/21Medacta announces first revision surgeries in the US using the unique-on-the-market and..
EQ
09/09Transcript : Medacta Group SA, H1 2022 Earnings Call, Sep 09, 2022
CI
09/09Swiss Orthopedic Group Medacta Lifts FY22 Outlook as H1 Revenue Grows; Profit Slows
MT
09/09Medacta : 2022 Half-Year Report
PU
09/09Medacta : 2022 Half-Year Presentation
PU
09/09Medacta Group SA reports strong revenue growth of 19.0% and adjusted EBITDA margin of 2..
EQ
09/09Medacta Group SA Revises Revenue Growth Guidance for the Full Year 2022
CI
09/08Medacta Group SA Reports Earnings Results for the Half Year Ended June 30, 2022
CI
07/29Transcript : Medacta Group SA, H1 2022 Earnings Call, Jul 29, 2022
CI
More news
Analyst Recommendations on MEDACTA GROUP SA
More recommendations
Financials
Sales 2022 428 M 418 M 418 M
Net income 2022 55,8 M 54,5 M 54,5 M
Net Debt 2022 137 M 134 M 134 M
P/E ratio 2022 30,1x
Yield 2022 0,73%
Capitalization 1 699 M 1 660 M 1 660 M
EV / Sales 2022 4,29x
EV / Sales 2023 3,70x
Nbr of Employees 1 421
Free-Float 30,4%
Chart MEDACTA GROUP SA
Duration : Period :
Medacta Group SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDACTA GROUP SA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 85,05 €
Average target price 110,94 €
Spread / Average Target 30,4%
EPS Revisions
Managers and Directors
Francesco Siccardi Chief Executive Officer
Corrado Farsetta Chief Financial Officer
Alberto Siccardi Non-Executive Chairman
Victor Waldemar Balli Lead Independent Non-Executive Director
Philippe A. Weber Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
MEDACTA GROUP SA-42.04%1 678
ABBOTT LABORATORIES-29.86%172 880
MEDTRONIC PLC-20.16%109 775
BECTON, DICKINSON AND COMPANY-6.27%65 700
HOYA CORPORATION-19.61%34 187
DEXCOM, INC.-37.92%32 714